Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines
Plasmodium falciparum malaria is a disease causing high morbidity and mortality rates worldwide, mainly in sub-Saharan Africa. Candidates have been identified for vaccines targeting the parasite’s blood stage; this stage is important in the development of symptoms and clinical complications. However...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2019
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/24091
- Acceso en línea:
- https://doi.org/10.3389/fmicb.2019.02712
https://repository.urosario.edu.co/handle/10336/24091
- Palabra clave:
- Ama 1 dico vaccine
Ama1 dico vaccine
Bk se36 vaccine
Erythrocyte binding protein 175 r2 ng vaccine
Gmz2 vaccine
Malaria vaccine
Msp3 lsp vaccine
Mva rh5 vaccine
P27a vaccine
Pfpebs vaccine
Placental malaria vaccine
Recombinant vaccine
Unclassified drug
Virus vector
Bioinformatics
Conformational transition
Cytokine release
Dna polymorphism
Emulsion
Gene expression system
Growth inhibition
Human
Humoral immunity
Immune response
Immunization
Immunogenicity
Malaria falciparum
Nonhuman
Phase 1 clinical trial (topic)
Phase 2 clinical trial (topic)
Review
Seroconversion
Vaccination
Antimalarial vaccine
Clinical trial
Immunogenicity
Malaria
Merozoite
Plasmodium falciparum
Vaccine
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_c0af02717de29057e65771a6f4318342 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/24091 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
title |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
spellingShingle |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines Ama 1 dico vaccine Ama1 dico vaccine Bk se36 vaccine Erythrocyte binding protein 175 r2 ng vaccine Gmz2 vaccine Malaria vaccine Msp3 lsp vaccine Mva rh5 vaccine P27a vaccine Pfpebs vaccine Placental malaria vaccine Recombinant vaccine Unclassified drug Virus vector Bioinformatics Conformational transition Cytokine release Dna polymorphism Emulsion Gene expression system Growth inhibition Human Humoral immunity Immune response Immunization Immunogenicity Malaria falciparum Nonhuman Phase 1 clinical trial (topic) Phase 2 clinical trial (topic) Review Seroconversion Vaccination Antimalarial vaccine Clinical trial Immunogenicity Malaria Merozoite Plasmodium falciparum Vaccine |
title_short |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
title_full |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
title_fullStr |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
title_full_unstemmed |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
title_sort |
Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines |
dc.subject.keyword.spa.fl_str_mv |
Ama 1 dico vaccine Ama1 dico vaccine Bk se36 vaccine Erythrocyte binding protein 175 r2 ng vaccine Gmz2 vaccine Malaria vaccine Msp3 lsp vaccine Mva rh5 vaccine P27a vaccine Pfpebs vaccine Placental malaria vaccine Recombinant vaccine Unclassified drug Virus vector Bioinformatics Conformational transition Cytokine release Dna polymorphism Emulsion Gene expression system Growth inhibition Human Humoral immunity Immune response Immunization Immunogenicity Malaria falciparum Nonhuman Phase 1 clinical trial (topic) Phase 2 clinical trial (topic) Review Seroconversion Vaccination Antimalarial vaccine Clinical trial Immunogenicity Malaria Merozoite Plasmodium falciparum Vaccine |
topic |
Ama 1 dico vaccine Ama1 dico vaccine Bk se36 vaccine Erythrocyte binding protein 175 r2 ng vaccine Gmz2 vaccine Malaria vaccine Msp3 lsp vaccine Mva rh5 vaccine P27a vaccine Pfpebs vaccine Placental malaria vaccine Recombinant vaccine Unclassified drug Virus vector Bioinformatics Conformational transition Cytokine release Dna polymorphism Emulsion Gene expression system Growth inhibition Human Humoral immunity Immune response Immunization Immunogenicity Malaria falciparum Nonhuman Phase 1 clinical trial (topic) Phase 2 clinical trial (topic) Review Seroconversion Vaccination Antimalarial vaccine Clinical trial Immunogenicity Malaria Merozoite Plasmodium falciparum Vaccine |
description |
Plasmodium falciparum malaria is a disease causing high morbidity and mortality rates worldwide, mainly in sub-Saharan Africa. Candidates have been identified for vaccines targeting the parasite’s blood stage; this stage is important in the development of symptoms and clinical complications. However, no vaccine that can directly affect morbidity and mortality rates is currently available. This review analyzes the formulation, methodological design, and results of active clinical trials for merozoite-stage vaccines, regarding their safety profile, immunological response (phase Ia/Ib), and protective efficacy levels (phase II). Most vaccine candidates are in phase I trials and have had an acceptable safety profile. GMZ2 has made the greatest progress in clinical trials; its efficacy has been 14% in children aged less than 5 years in a phase IIb trial. Most of the available candidates that have shown strong immunogenicity and that have been tested for their protective efficacy have provided good results when challenged with a homologous parasite strain; however, their efficacy has dropped when they have been exposed to a heterologous strain. In view of these vaccines’ unpromising results, an alternative approach for selecting new candidates is needed; such line of work should be focused on how to increase an immune response induced against the highly conserved (i.e., common to all strains), functionally relevant, protein regions that the parasite uses to invade target cells. Despite binding regions tending to be conserved, they are usually poorly antigenic and/or immunogenic, being frequently discarded as vaccine candidates when the conventional immunological approach is followed. The Fundación Instituto de Inmunología de Colombia (FIDIC) has developed a logical and rational methodology based on including conserved high-activity binding peptides (cHABPs) from the main P. falciparum biologically functional proteins involved in red blood cell (RBC) invasion. Once appropriately modified (mHABPs), these minimal, subunit-based, chemically synthesized peptides can be used in a system covering the human immune system’s main genetic variables (the human leukocyte antigen HLA-DR isotype) inducing a suitable, immunogenic, and protective immune response in most of the world’s populations. © Copyright © 2019 Salamanca, Gómez, Camargo, Cuy-Chaparro, Molina-Franky, Reyes, Patarroyo and Patarroyo. |
publishDate |
2019 |
dc.date.created.spa.fl_str_mv |
2019 |
dc.date.accessioned.none.fl_str_mv |
2020-05-26T00:08:31Z |
dc.date.available.none.fl_str_mv |
2020-05-26T00:08:31Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3389/fmicb.2019.02712 |
dc.identifier.issn.none.fl_str_mv |
1664302X |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/24091 |
url |
https://doi.org/10.3389/fmicb.2019.02712 https://repository.urosario.edu.co/handle/10336/24091 |
identifier_str_mv |
1664302X |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationTitle.none.fl_str_mv |
Frontiers in Microbiology |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 10 |
dc.relation.ispartof.spa.fl_str_mv |
Frontiers in Microbiology, ISSN:1664302X, Vol.10,(2019) |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076945544&doi=10.3389%2ffmicb.2019.02712&partnerID=40&md5=5c72db0f3d6039db49883eead08f426a |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Frontiers Media S.A. |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
bitstream.url.fl_str_mv |
https://repository.urosario.edu.co/bitstreams/e4f27273-a3f7-4bbe-8256-5a42b5b7b37c/download https://repository.urosario.edu.co/bitstreams/5ca38e1e-6000-4fd0-bddd-cb6282436d4c/download https://repository.urosario.edu.co/bitstreams/5c5a4d34-bbf7-4c2b-97a1-47f877c2126f/download |
bitstream.checksum.fl_str_mv |
7de6231a7a4e95fe75240fc98fbe949e 2e0aaa510ceab94ea1097aa98ff28a98 30ed4c094090892ea2a1ce0318afb84d |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167483686322176 |
spelling |
41bedf0b-35c8-4f78-884f-769f65f3f007-14e9a295b-a84c-4a61-8d2f-40ad823a34fe-13b7490f7-a153-437b-aba0-f5692e5bde64-14583a3bd-8b6b-4c00-903b-8afc253255fb-1ab9816de-63e2-4cc8-bf37-73bf0b8e9c5c-153332dc1-6365-41c0-8bf2-a42d23dcc8fc-19e3ba9df-fe89-48fe-9521-cc8f452d56f5-1796530656002020-05-26T00:08:31Z2020-05-26T00:08:31Z2019Plasmodium falciparum malaria is a disease causing high morbidity and mortality rates worldwide, mainly in sub-Saharan Africa. Candidates have been identified for vaccines targeting the parasite’s blood stage; this stage is important in the development of symptoms and clinical complications. However, no vaccine that can directly affect morbidity and mortality rates is currently available. This review analyzes the formulation, methodological design, and results of active clinical trials for merozoite-stage vaccines, regarding their safety profile, immunological response (phase Ia/Ib), and protective efficacy levels (phase II). Most vaccine candidates are in phase I trials and have had an acceptable safety profile. GMZ2 has made the greatest progress in clinical trials; its efficacy has been 14% in children aged less than 5 years in a phase IIb trial. Most of the available candidates that have shown strong immunogenicity and that have been tested for their protective efficacy have provided good results when challenged with a homologous parasite strain; however, their efficacy has dropped when they have been exposed to a heterologous strain. In view of these vaccines’ unpromising results, an alternative approach for selecting new candidates is needed; such line of work should be focused on how to increase an immune response induced against the highly conserved (i.e., common to all strains), functionally relevant, protein regions that the parasite uses to invade target cells. Despite binding regions tending to be conserved, they are usually poorly antigenic and/or immunogenic, being frequently discarded as vaccine candidates when the conventional immunological approach is followed. The Fundación Instituto de Inmunología de Colombia (FIDIC) has developed a logical and rational methodology based on including conserved high-activity binding peptides (cHABPs) from the main P. falciparum biologically functional proteins involved in red blood cell (RBC) invasion. Once appropriately modified (mHABPs), these minimal, subunit-based, chemically synthesized peptides can be used in a system covering the human immune system’s main genetic variables (the human leukocyte antigen HLA-DR isotype) inducing a suitable, immunogenic, and protective immune response in most of the world’s populations. © Copyright © 2019 Salamanca, Gómez, Camargo, Cuy-Chaparro, Molina-Franky, Reyes, Patarroyo and Patarroyo.application/pdfhttps://doi.org/10.3389/fmicb.2019.027121664302Xhttps://repository.urosario.edu.co/handle/10336/24091engFrontiers Media S.A.Frontiers in MicrobiologyVol. 10Frontiers in Microbiology, ISSN:1664302X, Vol.10,(2019)https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076945544&doi=10.3389%2ffmicb.2019.02712&partnerID=40&md5=5c72db0f3d6039db49883eead08f426aAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAma 1 dico vaccineAma1 dico vaccineBk se36 vaccineErythrocyte binding protein 175 r2 ng vaccineGmz2 vaccineMalaria vaccineMsp3 lsp vaccineMva rh5 vaccineP27a vaccinePfpebs vaccinePlacental malaria vaccineRecombinant vaccineUnclassified drugVirus vectorBioinformaticsConformational transitionCytokine releaseDna polymorphismEmulsionGene expression systemGrowth inhibitionHumanHumoral immunityImmune responseImmunizationImmunogenicityMalaria falciparumNonhumanPhase 1 clinical trial (topic)Phase 2 clinical trial (topic)ReviewSeroconversionVaccinationAntimalarial vaccineClinical trialImmunogenicityMalariaMerozoitePlasmodium falciparumVaccinePlasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic VaccinesarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Salamanca, David RicardoGómez, MarcelaCamargo, AnnyCuy-Chaparro, LauraMolina-Franky, JessicaReyes, CésarPatarroyo, Manuel ElkinPatarroyo, Manuel A.ORIGINALfmicb-10-02712.pdfapplication/pdf3106506https://repository.urosario.edu.co/bitstreams/e4f27273-a3f7-4bbe-8256-5a42b5b7b37c/download7de6231a7a4e95fe75240fc98fbe949eMD51TEXTfmicb-10-02712.pdf.txtfmicb-10-02712.pdf.txtExtracted texttext/plain84731https://repository.urosario.edu.co/bitstreams/5ca38e1e-6000-4fd0-bddd-cb6282436d4c/download2e0aaa510ceab94ea1097aa98ff28a98MD52THUMBNAILfmicb-10-02712.pdf.jpgfmicb-10-02712.pdf.jpgGenerated Thumbnailimage/jpeg4617https://repository.urosario.edu.co/bitstreams/5c5a4d34-bbf7-4c2b-97a1-47f877c2126f/download30ed4c094090892ea2a1ce0318afb84dMD5310336/24091oai:repository.urosario.edu.co:10336/240912022-05-02 07:37:21.39511https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |